Combined application of the traditional Chinese herbal medicine, Renvatinib, and Carrelizumab in a patient with primary liver cancer: A case report and literature review
Advanced Chinese Medicine · 2024
DOI: 10.1002/acm4.20 ↗Abstract
Abstract The patient was diagnosed with primary liver cancer featuring intrahepatic metastasis (Barcelona stage B; Stage IIB), hepatitis B infection, and post‐hepatitis B cirrhosis during the period of compensated liver function. Following a 7‐month regimen combining traditional Chinese herbal medicine (TCHM) with Renvatinib and Carrelizumab, the patient exhibited favorable tolerability, no bleeding risks, and stable tumor progression. The effectiveness of TCHM in this case was marked by significant symptom alleviation, reduced serum molecular markers, minimized adverse reactions, and obviated surgical intervention. Blood tests displayed alpha‐fetoprotein levels ranging from 8.85 to 20.65 IU/mL, with no increase in bleeding risks.
EUVIMED